Abstract
A novel clinically applicable biomarker for testing HRD status based on the mutational signatures: Results for the phase 2 trial of olaparib maintenance monotherapy in patients with primary high-grade ovarian carcinoma (2271)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have